Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

20 Dec 2018

Abstract excerpt

INTRODUCTION: Therapeutic options for diffuse malignant peritoneal mesothelioma (DMPM) are limited to surgery and locoregional chemotherapy. Despite improvements in survival rates, patients eventually succumb to disease progression. We investigated splicing deregulation both as molecular prognostic factor and potential novel target in DMPM, while we tested modulators of SF3b complex for antitumor activity....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Mechanics and Interactions
Share to Medical Imaging and Pathology Studies
Share to Occupational and environmental lung diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30581150
DOI: 10.1016/j.ebiom.2018.12.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesotheliomaPMID 30581150Read ↗

FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic targetSemantic proximity Read ↗

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugSemantic proximity Read ↗

SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalancesSemantic proximity Read ↗

Spliceosome Inhibition in <i>SF3B1</i>-Mutated Uveal MelanomaSemantic proximity Read ↗

A New Molecular (P)Layer in Pseudomyxoma Peritonei: The Splicing Machinery is Dysregulated and Linked to Low SurvivalSemantic proximity Read ↗

Molecular characterization of diffuse malignant peritoneal mesotheliomaSemantic proximity Read ↗

The Impact of Spliceosome Inhibition in SF3B1-Mutated Uveal Melanoma.Semantic proximity Read ↗

Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progressionSemantic proximity Read ↗

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinomaSemantic proximity Read ↗

Dysregulated Spliceosome Activity Involves Increased Intron Retention Plus Upregulation and Phosphorylation of SF3B1 in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.Semantic proximity Read ↗

Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.